Grail provides update on PATHFINDER 2, NHS-Galleri clinical trials

Grail provided an update on the PATHFINDER 2 and NHS-Galleri registrational clinical trials evaluating the Galleri multi-cancer early detection, or MCED, test. Grail has completed the PATHFINDER 2 study’s planned enrollment of more than 35,000 participants who are eligible for guideline-recommended cancer screening at more than 30 healthcare institutions in North America. In addition, Grail has completed the third and final round of study visits for the NHS-Galleri trial, which enrolled more than 140,000 participants.